Angelia V Bassenden

List of Publications by Year
in descending order

12	273	1307594 7	1281871 11
papers	citations	h-index	g-index

12	12	12	428
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	De novo TRPV4 Leu619Pro variant causes a new channelopathy characterised by giant cell lesions of the jaws and skull, skeletal abnormalities and polyneuropathy. Journal of Medical Genetics, 2022, 59, 305-312.	3.2	6
2	Structural basis for plazomicin antibiotic action and resistance. Communications Biology, 2021, 4, 729.	4.4	13
3	Structural and phylogenetic analyses of resistance to next-generation aminoglycosides conferred by AAC(2â€²) enzymes. Scientific Reports, 2021, 11, 11614.	3.3	9
4	Bisphosphoglycerate Mutase Deficiency Protects against Cerebral Malaria and Severe Malaria-Induced Anemia. Cell Reports, 2020, 32, 108170.	6.4	7
5	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell, 2020, 183, 1617-1633.e22.	28.9	93
6	Revisiting the Catalytic Cycle and Kinetic Mechanism of Aminoglycoside O-Nucleotidyltransferase(2â€³): A Structural and Kinetic Study. ACS Chemical Biology, 2020, 15, 686-694.	3.4	0
7	ZBTB7B (ThPOK) Is Required for Pathogenesis of Cerebral Malaria and Protection against Pulmonary Tuberculosis. Infection and Immunity, 2020, 88, .	2.2	6
8	DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis. Journal of Clinical Investigation, 2020, 130, 1479-1490.	8.2	31
9	TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw. Nature Communications, 2018, 9, 4572.	12.8	58
10	Effect of solvent and protein dynamics in ligand recognition and inhibition of aminoglycoside adenyltransferase 2â€³â€‰a. Protein Science, 2017, 26, 1852-1863.	7.6	2
11	Structural Analysis of the Tobramycin and Gentamicin Clinical Resistome Reveals Limitations for Next-generation Aminoglycoside Design. ACS Chemical Biology, 2016, 11, 1339-1346.	3.4	23
12	Drug-target networks in aminoglycoside resistance: hierarchy of priority in structural drug design. MedChemComm, 2016, 7, 103-113.	3.4	25